|

US has accepted 30 mln doses of hydroxychloroquine sulfate donated by Novartis's Sandoz as possible treatments for COVID-19

US HHS says it has accepted 30 mln doses of hydroxychloroquine sulfate donated by Novartis's Sandoz as possible treatments for COVID-19 patients.

Hydroxychloroquine, as well as a related drug, chloroquine, have been evaluated for use against COVID-19 in clinical trials around the world. Hydroxychloroquine is a derivative of chloroquine and is reported to be a less toxic form of the latter drug. US President Donald Trump has been in favour of the use of the chloroquine against the disease based on early data evaluating its efficacy against the novel coronavirus disease.

Key notes

  • US HHS says accepts donations of medicine to strategic national stockpile as possible treatments for COVID-19 patients.
  • US HHS says accepted 30 mln doses of hydroxychloroquine sulfate donated by Novartis's Sandoz as possible treatments for COVID-19 patients.
  • US HHS says accepted 1 mln doses of chloroquine phosphate donated by Bayer pharmaceuticals as possible treatments for COVID-19 patients.

Market implications

Watch and see. Markets are risk-off and taking each and every headline with respect to a cure with a pinch of salt. More on this here: US Pres. Trump: Working to speed up FDA approval on sterilizing medical masks for reuse

Author

Ross J Burland

Ross J Burland, born in England, UK, is a sportsman at heart. He played Rugby and Judo for his county, Kent and the South East of England Rugby team.

More from Ross J Burland
Share:

Markets move fast. We move first.

Orange Juice Newsletter brings you expert driven insights - not headlines. Every day on your inbox.

By subscribing you agree to our Terms and conditions.

Editor's Picks

EUR/USD eases from around 1.1800 after US GDP figures

The US Dollar is finding some near-term demand after the release of the US Q3 GDP. According to the report, the economy expanded at an annualized rate of 4.3% in the three months to September, well above the 3.3% forecast by market analysts.

GBP/USD retreats below 1.3500 on modest USD recovery

GBP/USD retreats from session highs and trades slightly below 1.3500 in the second half of the day on Tuesday. The US Dollar stages a rebound following the better-than-expected Q3 growth data, limiting the pair's upside ahead of the Christmas break.

Gold to challenge fresh record highs

Gold prices soared to $4,497 early on Monday, as persistent US Dollar weakness and thinned holiday trading exacerbated the bullish run. The bright metal eases following the release of an upbeat US Q3 GDP reading, as USD finds near-term demand in the American session.

Crypto Today: Bitcoin, Ethereum, XRP decline as risk-off sentiment escalates

Bitcoin remains under pressure, trading above the $87,000 support at the time of writing on Tuesday. Selling pressure has continued to weigh on the broader cryptocurrency market since Monday, triggering declines across altcoins, including Ethereum and Ripple.

Ten questions that matter going into 2026

2026 may be less about a neat “base case” and more about a regime shift—the market can reprice what matters most (growth, inflation, fiscal, geopolitics, concentration). The biggest trap is false comfort: the same trades can look defensive… right up until they become crowded.

Dogecoin ticks lower as low Open Interest, funding rate weigh on buyers

Dogecoin extends its decline as risk-off sentiment dominates across the crypto market. DOGE’s derivatives market remains weak amid suppressed futures Open Interest and perpetual funding rate.